Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

Key facts

Sponsor

Safaa AA Khaled

Principal Investigator

doha M ali, MD

Assiut University

Intervention

BCR-ABL gene PCR(diagnostic_test)

Enrollment

80 enrolled

Eligibility

18 years · All sexes

Timeline

2020 – 2022

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07441694
  Study of INCA036978 in Participants With Myeloproliferative Neoplasms
  Incyte Corporation
• RECRUITINGPHASE2NCT07148947
  Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
  University of Washington
• RECRUITINGPHASE2NCT07228624
  Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
  Fred Hutchinson Cancer Center
• RECRUITINGNANCT07119970
  Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
  University Hospital, Bordeaux
• RECRUITINGPHASE2NCT06661915
  A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
  National Cancer Institute (NCI)
• RECRUITINGPHASE3NCT06468033
  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
  PharmaEssentia
• RECRUITINGNCT07165535
  Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
  University of Milano Bicocca
• RECRUITINGNANCT05745285
  Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
  University of Miami

See all trials for Myeloproliferative neoplasm →